Browse drugs

…pse risk (1.35, 1.16 to 1.57) and RAW (1.77, 1.07 to 2.94) than ocrelizumab. Alemtuzumab was associated with higher ARR (0.18 vs 0.12, p<0.…

…alth outcomes, indicating that breastfeeding is compatible with ocrelizumab.ruth.dobson@qmul.ac.uk…

… biochemical parameters. Budesonide and prednisone were weaned. Tofacitinib continues.Conclusions CD20+ cells play a regulatory and protect…

…se modifying therapy influence CD19+ B-cell repopulation during ocrelizumab treatment. With further elucidation of the association between …

…ffectively slow disease progression with a good safety profile. Ocrelizumab, a monoclonal antibody targeting CD20-positive B cells, is used…

…04998812) is a prospective Phase IV, open-label study measuring ocrelizumab placental transfer, infant B-cell levels and detailed maternal …

…rategy after discontinuation of B-cell depleting therapies like ocrelizumab in people with multiple sclerosis (pwMS) remains uncertain, par…

…-CD20 therapy (768 on rituximab and 509 on ocrelizumab) and 677 natalizumab. Natalizumab significantly reduced ARR compared with anti-CD20 …

…gnancies from the Roche safety database were analysed. Maternal ocrelizumab exposure was defined as ≥1 infusion; in utero exposure was defi…

…e unit utilisation after switching established patients from IV ocrelizumab to SC injection.Methods Patients completed a questionnaire asse…

…minated Ureaplasma infection.Discussion Both cases suggest that ocrelizumab treatment can lead to severe vaginitis, even in the absence of …

… a patient with enterovirus rhombencephalitis in the context of ocrelizumab treatment for multiple sclerosis.Case A 41 year old female deve…